Purpose: To investigate the factors associated with maximum visual improvement (peak vision) gain and the risk factors of peak vision loss and multiple recurrences in myopic macular neovascularization undergoing antivascular endothelial growth factor therapy.
Methods: Retrospective study of 310 eyes with active myopic macular neovascularization and median follow-up of 3.5 years.